Harmony Biosciences Holdings, Inc. Common Stock (HRMY) — 分析摘要
Harmony Biosciences Holdings, Inc. Common Stock（HRMY）的市值为2.04十亿美元，最近一年的营收同比增长了+21.5%。净利润率为18.3%。当前市盈率为14.0倍。
核心要点
- 营收同比变化+21.5%
- 净利润率18.3%
- 市盈率14.0倍
与PHARMACEUTICAL PREPARATIONS板块的其他公司相比，HRMY的营收增长为+21.5%，市盈率为14.0倍。
Harmony Biosciences Holdings, Inc. Common Stock (HRMY)
更新 — ET · 来源 POLYGON
红旗与风险提示无重大红旗
基于最新财报，没有触发重大的信用、利润率或趋势红旗。
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
行业
PHARMACEUTICAL PREPARATIONS
员工人数
293
总部
PLYMOUTH MEETING, PA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。